{"disease":{"id":"type-1-gaucher-disease","name":"Type 1 Gaucher disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"taliglucerase-alfa","indication_name":"Type 1 Gaucher Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TALIGLUCERASE ALFA","company_name":"","drug_phase":"marketed","molecular_target":"glucocerebrosidase","drug_class":"Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC]","quality_score":45,"revenue":null,"mechanism":"ELELYSO replaces deficient glucocerebrosidase, reducing glucocerebroside accumulation in Gaucher cells."},{"drug_id":"elelyso","indication_name":"Type 1 Gaucher disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elelyso","generic_name":"Taliglucerase Alfa","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Glucocerebroside (substrate); mannose receptors on cell surface","drug_class":"Enzyme replacement therapy","quality_score":10,"revenue":null,"mechanism":"Recombinant glucocerebrosidase enzyme replacement therapy that catalyzes hydrolysis of glucocerebroside to glucose and ceramide."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT05447494","title":"Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"CANbridge (Suzhou) Bio-pharma Co., Ltd.","has_results":false},{"nct_id":"NCT03746587","title":"Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":39,"lead_sponsor_name":"ZevraDenmark","has_results":false},{"nct_id":"NCT00433147","title":"A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT00446550","title":"A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT02843035","title":"Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT00813865","title":"A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT04836377","title":"A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02","phase":"","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"AVROBIO","has_results":false},{"nct_id":"NCT03021941","title":"Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Pfizer","has_results":false}],"total":9},"guidelines":[{"drug_id":"elelyso","guideline_body":"FDA label","recommendation":"ELELYSO is indicated for the treatment of patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}